D. E. Shaw & Co., Inc. Kinnate Biopharma Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $101,526 - $237,212	94,885 Added 170.01%	150,695 $357,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $5,932 - $14,229	-4,299 Reduced 7.15%	55,810 $78,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $140,053 - $411,145	60,109 New	60,109 $182,000
Q1 2022 May 16, 2022	SELL	$7.73 - $17.99 $108,134 - $251,662	-13,989 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $238,903 - $368,924	-14,479 Reduced 50.86%	13,989 $248,000
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $137,332 - $191,772	7,711 Added 37.15%	28,468 $655,000
Q2 2021 Aug 16, 2021	SELL	$22.19 - $31.55 $46,332 - $65,876	-2,088 Reduced 9.14%	20,757 $483,000
Q1 2021 May 17, 2021	BUY	$26.99 - $40.0 $616,586 - $913,800	22,845 New	22,845 $712,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.